<DOC>
	<DOC>NCT02864706</DOC>
	<brief_summary>This protocol is written to describe the procedures for a single 5, 6 or 7 year follow-up control visit of patients who participated in the 12-month SCHEDULE-study and the following 3-year follow-up examination/visit. The aim of this 5 to 7-year follow-up visit is to examine the effect of long term treatment, i.e. 5, 6 or 7 years, with early initiation of everolimus (CerticanÂ®) and early elimination of cyclosporine (CsA), compared to standard immunosuppressive regimen including CsA, on renal and heart function. During the time period of this follow-up examinations, this visit will be performed as part of a routine annual visit 5, 6 or 7 years since transplantation (and inclusion in the original SCHEDULE study).</brief_summary>
	<brief_title>SCHEDULE Follow Up Visit 5-7 yr</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients who participated in the SCHEDULE 12month main study, and who completed the 3 year followup visit Patients who are coming for a regular annual clinic visit 5 to 7 years after randomization in the main study Obtaining of a separate signed patient informed consent will be required for participation in this followup examination. Patients with a retransplanted heart since the original SCHEDULE study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>